, Volume 33, Issue 6, pp 2061-2068
Date: 29 Jul 2012

EGFR exon mutation distribution and outcome in non-small-cell lung cancer: a Portuguese retrospective study

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access


Epidermal growth factor receptor (EGFR) mutations play a predictive role in advanced stages of non-small-cell lung cancer (NSCLC) patients. We conducted this study in order to assess EGFR status in a Portuguese population and its role in NSCLC patients' outcomes. Patients were submitted to EGFR assessment by high-resolution melting and/or direct sequencing. Kaplan–Meier curve was used to assess overall survival and progression-free survival (PFS). Two hundred forty eight out of 322 participants were assessed for EGFR status. Forty-two patients (16.9 %) presented EGFR-mutated status: one patient (2.4 %) presented exon 18; 21 patients (50 %), exon 19; one patient (2.4 %), exon 20; and 18 patients (45.2 %), exon 21 mutations, p < 0.001. PFS was not assessed (n.a.) for patient with exon 18 mutation, and for the other patients with mutations, it was 7 months (3.96–10.03) (exon 19), <1 month (exon 20), and 7 months (0–14.2) (exon 21) (p = 0.027). Overall survival (OS) was 11 months (exon 18), 11 months (1–18) (exon 19), 1 month (exon 20), and 7.5 months (2–70) (exon 21) (p = n.a). This study suggests that the EGFR mutation is herein observed in a higher proportion than expected for a Caucasian population, and OS is a little less than that published in the literature.